Delving into the Latest Updates on JenKem Technology (Tianjin) Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Nervous System Diseases

Respiratory Diseases

Polymer

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Polymer	1

Top 5 Target	Count

Top I(DNA topoisomerase I)	1

Primary objectives: 1) To evaluate the safety and tolerability of JK1201I in patients with small cell lung cancer; 2) To determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of JK1201I. Secondary objectives: 1) To investigate the pharmacokinetic properties of JK1201I in patients with small cell lung cancer; 2) To observe the preliminary efficacy of JK1201I.

Start Date04 Nov 2021

Sponsor / Collaborator

JenKem Technology (Tianjin) Co., Ltd.

CTR20182496

/ RecruitingPhase 1

注射用聚乙二醇伊立替康单次联合多次给药用于恶性实体瘤患者的安全性、耐受性和药代动力学研究

[Translation] Safety, tolerability and pharmacokinetics of single combined with multiple doses of polyethylene glycol irinotecan for injection in patients with malignant solid tumors

主要目的为：评价注射用聚乙二醇伊立替康对恶性实体肿瘤患者的安全性和耐受性；并确定其剂量限制性毒性（DLT）和最大耐受剂量（MTD）。次要目的为：考察其在恶性实体肿瘤患者体内的药代动力学特性，并获取药代动力学参数；观察注射用聚乙二醇伊立替康的初步疗效，为后续临床试验推荐剂量和给药方式提供依据。

[Translation]

The primary objectives are to evaluate the safety and tolerability of polyethylene glycol irinotecan for injection in patients with malignant solid tumors and to determine its dose-limiting toxicity (DLT) and maximum tolerated dose (MTD). The secondary objectives are to investigate its pharmacokinetic properties in patients with malignant solid tumors and obtain pharmacokinetic parameters; to observe the preliminary efficacy of polyethylene glycol irinotecan for injection and provide a basis for the recommended dose and administration method for subsequent clinical trials.

Start Date23 Jun 2019

Sponsor / Collaborator

JenKem Technology (Tianjin) Co., Ltd.

100 Clinical Results associated with JenKem Technology (Tianjin) Co., Ltd.

Login to view more data

0 Patents (Medical) associated with JenKem Technology (Tianjin) Co., Ltd.

Login to view more data

100 Deals associated with JenKem Technology (Tianjin) Co., Ltd.

Login to view more data

100 Translational Medicine associated with JenKem Technology (Tianjin) Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 30 Oct 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3

1

Login to view more data